Hepatitis B Questions and Answers for Health Professionals

Index of Questions

Overview and Statistics

What are the case definitions for reportable HBV infections?

Case definitions have been developed by CDC, in collaboration with the Council of State and Territorial Epidemiologists, to provide uniform clinical and laboratory-testing criteria for the identification and reporting of nationally notifiable infectious diseases. The case definitions for acute, chronic, and perinatal hepatitis B are available at the following links:

How many new HBV infections occur annually in the United States?

In 2018, a total of 3,322 cases of acute hepatitis B were reported to CDC, for an overall incidence rate of 1.0 cases per 100,000 population (1). After adjusting for under-ascertainment and under-reporting, an estimated 21,600 acute hepatitis B cases occurred in 2018 (1).

Has the rate of new HBV infections in the United States changed?

The rate of reported acute hepatitis B cases has remained stable over the past decade, with a slight increase occurring in 2017 (1).

Line chart with years 2011-2018 along the x axis and reported cases per 100,000 population along the y axis.

Source: CDC, National Notifiable Diseases Surveillance System.

How common is chronic HBV infection in the United States?

Between 880,000 to 1.89 million people are living with HBV infection in the United States (2,3); two-thirds of whom may be unaware of their infection (4). Chronic hepatitis B disproportionately affects people born outside the United States; while accounting for only 14% of the US general population, non–US-born people account for 69% of the US population living with chronic HBV infection (2,3,5).

How many deaths can be attributed to chronic HBV infection?

In 2018, a total of 1,649 US death certificates had HBV recorded as an underlying or contributing cause of death (6). However, this is a conservative estimate.


Transmission, Symptoms, and Treatment

How is HBV transmitted?

HBV is transmitted through activities that involve percutaneous (i.e., puncture through the skin) or mucosal contact with infectious blood or body fluids (e.g., semen and saliva), including

  • sex with a partner who has HBV infection;
  • injection drug use that involves sharing needles, syringes, or drug-preparation equipment;
  • birth to a person who has HBV infection;
  • contact with blood from or open sores on a person who has HBV infection;
  • exposures to needle sticks or sharp instruments; and
  • sharing certain items with a person who has HBV infection that can break the skin or mucous membranes (e.g., razors, toothbrushes, and glucose monitoring equipment), potentially resulting in exposure to blood.

How long does HBV survive outside the body?

HBV can survive outside the body and remains infectious for at least 7 days (7).

What should be used to clean environmental surfaces potentially contaminated with HBV?

Any blood spills (including dried blood, which can still be infectious) should be disinfected using a 1:10 dilution of one part household bleach to 9 parts water. Gloves should be worn when cleaning up any blood spills.

Who is at risk for HBV infection?

The following populations are at increased risk for becoming infected with HBV:

  • Infants born to people with HBV infection
  • Sex partners of people with HBV infection
  • Men who have sex with men
  • People who inject drugs
  • Household contacts or sexual partners of known people with chronic HBV infection
  • Health care and public safety workers at risk for occupational exposure to blood or blood-contaminated body fluids
  • Patients on hemodialysis

Who should be screened for HBV?

CDC recommends that the following people be screened for HBV infection (8,9,10):

  • People born in countries with prevalence of HBV infection ≥2%
  • People born in the United States not vaccinated as infants whose parents were born in regions with high rates of HBV infection (HBsAg prevalence of ≥8%)
  • Men who have sex with men
  • People who inject drugs
  • People with HIV
  • Household and sexual contacts of people with HBV infection
  • People requiring immunosuppressive therapy
  • People with end-stage renal disease (including patients on hemodialysis)
  • Blood and tissue donors
  • People with elevated alanine aminotransferase levels (>19 IU/L for women and >30 IU/L for men)
  • Pregnant people (hepatitis B surface antigen [HBsAg] only is recommended)
  • Infants born to people with HBV infection (HBsAg and antibody to hepatitis B surface antigen [anti-HBs] only are recommended)

Are international travelers at risk for HBV infection?

The risk for HBV infection in international travelers is generally low, except for certain travelers to regions where the prevalence of chronic HBV infection is high or intermediate (i.e., HBsAg prevalence of ≥2%). Hepatitis B vaccination should be administered to unvaccinated people traveling to those countries. More information about hepatitis B and travel is available from CDC’s Travelers’ Health site.

What are the signs and symptoms of HBV infection?

Not all people with acute HBV infection have symptoms. The presence of signs and symptoms varies by age. Most children <5 years of age and newly infected immunosuppressed adults are generally asymptomatic, whereas 30%–50% of people age ≥5 years have signs and symptoms (11). When present, signs and symptoms of acute HBV infections can include:

  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • dark urine
  • clay-colored stool
  • joint pain
  • jaundice

Most people with chronic HBV infection are asymptomatic and have no evidence of liver disease or injury. However, some people develop chronic hepatitis (elevation of AST/ALT), cirrhosis, or hepatocellular carcinoma (i.e., primary liver cancer).

What is the incubation period for hepatitis B?

If symptoms occur, they begin an average of 90 days (range: 60–150 days) after exposure to HBV (6,12).

When symptoms of acute hepatitis B occur, how long do they usually last?

Symptoms typically last for several weeks but can persist for up to 6 months (6,12).

How serious is acute HBV infection?

Acute infection ranges from asymptomatic or mild disease to fulminant hepatitis, although the latter occurs only rarely. Disease is more severe among adults age >60 years (1).

How serious is chronic HBV infection?

Approximately 25% of people who become chronically infected during childhood and 15% of those who become chronically infected after childhood die prematurely from cirrhosis or liver cancer, and most remain asymptomatic until onset of cirrhosis or end-stage liver disease (13,14).

How likely is HBV infection to become chronic?

The risk for chronic infection varies according to the age at infection and is greatest among young children. Approximately 90% of infants and 25%–50% of children aged 1–5 years will remain chronically infected with HBV. By contrast, approximately 95% of adults recover completely from HBV infection and do not become chronically infected (11).

What tests are used to identify patients with hepatitis B?

Three different serologic tests are needed (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs], and total hepatitis B core antibody [anti-HBc]) to determine whether a patient

  • has acute or chronic HBV infection and is in need of post-test counseling and linkage to care (15),
  • is immune to HBV as a result of prior infection or vaccination (in conjunction with vaccination history), or
  • is susceptible to infection and in need of vaccination.

For detailed information about HBV screening and specific serologic markers, see Interpretation of Hepatitis B Serologic Test Results.

How long after exposure to HBV can HBsAg be detected in an infected patient’s blood?

HBsAg will be detected in an infected person’s blood an average of 4 weeks (range: 1–9 weeks) after exposure to the virus. About half of patients will no longer be infectious by 7 weeks after onset of symptoms, and all patients who do not remain chronically infected will be HBsAg-negative by 15 weeks after onset of symptoms (12).

Where can I learn more about HBV serology?

CDC offers an online training that covers hepatitis B serology.

How is HBV infection treated?

People with acute infection are provided supportive treatment depending on their symptoms. For people with chronic infection, several antiviral medications are available (16); these patients require linkage to care with regular monitoring to prevent liver damage and/or hepatocellular carcinoma.  The American Association for the Study of Liver Diseases (AASLD) has published practice guidelines for the treatment of chronic hepatitis B.

What is HBV reactivation?

HBV reactivation is the abrupt reappearance or rise in HBV DNA in a patient with previously inactive chronic or resolved hepatitis B. It is often accompanied by a flare in disease activity with elevation of liver enzymes with or without symptoms. HBV reactivation can be severe, resulting in death (17).

Who is at greatest risk for HBV reactivation?

Patients who test positive for both anti-HBc and HBsAg are at substantially higher risk of reactivation than are those who are positive for both anti-HBc and anti-HBs. Others at risk include people

  • undergoing cancer chemotherapy;
  • taking immunosuppressive therapy, including
    • Rituximab and other drugs that target B lymphocytes (black box warning),
    • high-dose steroids, and
    • anti-TNF agents;
  • with HIV infection who have discontinued therapy with antiretroviral drugs that also have activity against HBV;
  • undergoing solid organ or bone marrow transplantation; and
  • being treated for HCV coinfection.

For more information on risk, monitoring, and prevention of HBV reactivation, see the American Gastroenterological Association’s Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy and AGA Institute Guidelines on Hepatitis B Reactivation (HBVr): Clinical Decision Support Tool.

Are patients undergoing treatment for HCV at risk for HBV reactivation?

Because of recent reports of HBV reactivation in HCV coinfected patients receiving direct acting antiviral (DAA) therapy for HCV infection (18), all patients initiating HCV DAA therapy should be tested for HBV infection with HBsAg, anti-HBs, and anti-HBc. People testing positive for HBsAg and/or anti-HBc should be monitored while receiving HCV treatment. More information about treating HBV/HCV coinfected patients can be found at http://hcvguidelines.org and https://www.aasld.org/publications/practice-guidelines-0.

What is HBV/hepatitis D virus (HDV) superinfection?

Superinfection occurs when people with chronic, active HBV infection are subsequently infected with HDV. Superinfection exacerbates the symptoms of the chronic HBV infection and can lead to acute liver failure (see Hepatitis D FAQs for Professionals).


Hepatitis B Vaccination

Who should be vaccinated against hepatitis B?

The Advisory Committee on Immunization Practices (ACIP) recommends that the following people should receive hepatitis B vaccination:

  • All infants
  • Unvaccinated children aged <19 years
  • Adults aged 19 through 59 years
  • Adults aged 60 years and older with risk factors for hepatitis B

The following groups may receive hepatitis B vaccination:

  • Adults aged 60 years and older without known risk factors for hepatitis B

Risk factors for hepatitis B

  • People at risk for infection by sexual exposure
    • Sex partners of people who test positive for hepatitis B surface antigen (HBsAg)
    • Sexually active people who are not in a long-term, mutually monogamous relationship (e.g., people with more than one sex partner during the previous 6 months)
    • People seeking evaluation or treatment for a sexually transmitted infection
    • Men who have sex with men
  • People at risk for infection by percutaneous or mucosal exposure to blood
    • People with current or recent injection use
    • Household contacts of people who test positive for HBsAg
    • Residents and staff of facilities for people with developmental disabilities
    • Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids
    • People on maintenance dialysis, including in-center or home hemodialysis and peritoneal dialysis, and people who are predialysis
    • People with diabetes at the discretion of the treating clinician
  • Others
    • International travelers to countries with high or intermediate levels of endemic hepatitis B virus (HBV) infection (HBsAg prevalence of ≥2%)
    • People with hepatitis C virus infection
    • People with chronic liver disease (including, but not limited to, people with cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
    • People with HIV infection
    • People who are incarcerated

Is hepatitis B vaccination recommended in certain settings?

Yes. In certain health care, evaluation, or treatment settings, a high proportion of clients have known risk factors for HBV infection. ACIP recommends universal vaccination of adults who receive care in those settings, which include:

  • sexually transmitted disease treatment facilities,
  • HIV testing and treatment facilities,
  • facilities providing drug-abuse treatment and prevention services,
  • health-care settings targeting services to people who inject drugs,
  • correctional facilities,
  • health care settings targeting services to men who have sex with men,
  • chronic hemodialysis facilities and end-stage renal disease programs, and
  • institutions and nonresidential day care facilities for people with developmental disabilities.

What are the hepatitis B vaccines licensed for use in the United States?

Three single-antigen vaccines, one three-antigen vaccine,  and three combination vaccines are currently licensed in the United States.

Single-antigen hepatitis B vaccines

  • Engerix-B
  • Recombivax HB
  • Heplisav-B

Three-antigen hepatitis B vaccines

  • PreHevbrio (19)

Combination vaccines

  • Pediarix: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine
  • Twinrix: Combined hepatitis A and hepatitis B vaccine
  • Vaxelis: Combined DTaP, IPV, Haemophilus influenzae type b, and hepatitis B vaccine

What are the recommended schedules for hepatitis B vaccination?

The vaccination schedule most often used for children and adults is three intramuscular injections, the second and third doses administered at 1 and 6 months, respectively, after the first dose. Alternate schedules have been approved for certain vaccines and/or populations. A new formulation, Heplisav-B (HepB-CpG), is approved for two doses, 1 month apart.

What are the recommended doses of hepatitis B vaccines?

Recommended doses of currently licensed formulations of hepatitis B vaccine, by age group and vaccine type
Hepatitis B Vaccine*, Age Group (yrs) Dose (µg) Vol (mL) Schedule
Recombivax HB
Infants (<1 yr) 5 0.5 3-doses at age 0, 1–2, 6–18 mos
Children (1–10 yrs) 5 0.5 3 doses at 0, 1–2, 6 mos
Adolescents (11–19 yrs) 5 0.5 3 doses at 0, 1, 6 mos

 

Adults (≥20 yrs) 10 1
Patients on hemodialysis and other immune-compromised persons, <20 yrs§ 5 0.5
Patients on hemodialysis and other immune-compromised persons, ≥20 yrs 40 1
Engerix-B
Infants (<1 yr) 10 0.5 3-doses at age 0, 1–2, 6–18 mos
Children (1–10 yrs) 10 0.5 3 doses at 0, 1–2, 6 mos
Adolescents (11–19yrs) 10 0.5 3 doses at 0, 1, 6 mos
Adults (≥20 yrs) 20 1
Patients on hemodialysis and other immune-compromised persons, <20 yrs§ 10 0.5
Patients on hemodialysis and other immune-compromised persons, ≥20 yrs 40 2 4 doses at 0, 1, 2, 6 mos
Heplisav-B
Adults (≥18 yrs**) 20 0.5 2 doses at 0 and 1 mos
PreHevbrio (FDA-approved in 2021)
Adults (≥18 yrs**) 10 1 3 doses at 0, 1, 6 mos
Pediarix (combination hepatitis B, diphtheria, tetanus, acellular pertussis, and inactivated poliovirus)
Infants (<1 yr) 10 0.5 3-doses at age 0, 1–2, 6–18 mos
Children (1–6 yrs) †† 10 0.5 3 doses at 0, 1–2, 6 mos
Vaxelis (combination diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B)
Infants (<1 yr) 10 0.5 3 doses at age 0, 1–2, 6–18 mos
Children (1–4 yrs) §§ 10 0.5 3 doses at 0, 1–2, 6 mos
Twinrix (combination hepatitis A-hepatitis B) ¶¶
Adults (≥18 yrs) 20 1 3 doses at 0, 1, 6 mos (standard) or

4 doses at 0, 7d, 21–30 d, 12 mos (accelerated)

* Refer to package inserts for further information. For all ages, when the hepatitis B vaccine schedule is interrupted, the vaccine series does not need to be restarted. If a 3-dose series is interrupted after the first dose, the second dose should be administered as soon as possible, and the second and third doses should be separated by an interval of at least 8 weeks. If only the third dose has been delayed, it should be administered as soon as possible. The final dose of a 3-dose series vaccine must be administered at least 8 weeks after the second dose and should follow the first dose by at least 16 weeks; the minimum interval between the first and second doses is 4 weeks. Inadequate doses of hepatitis B vaccine or doses received after a shorter-than-recommended dosing interval should be readministered, using the correct dosage or schedule. Vaccine doses administered ≤4 days before the minimum interval or age are considered valid. Because of the unique accelerated schedule for Twinrix, the 4-day guideline does not apply to the first three doses of this vaccine when administered on a 0-day, 7-day, 21–30-day, and 12-month schedule. PreHevbrio is a three-antigen HepB vaccine that was FDA approved in 2021.

A 2-dose schedule of Recombivax HB adult formulation (10 µg) is licensed for adolescents aged 11 through 15 years. When scheduled to receive the second dose, adolescents aged 16 years or older should be switched to a 3-dose series, with doses 2 and 3 consisting of the pediatric formulation administered on an appropriate schedule.

§ Higher doses might be more immunogenic, but no specific recommendations have been made.

Engerix-B for adults on hemodialysis: Administer series of 4 doses (2 mL each) as a single 2-mL dose or as two 1-mL doses on a 0-, 1-, 2-, 6-month schedule. Recombivax HB for adults on hemodialysis is a 3-dose series.

** Data on Heplisav-B and PreHevbrio are currently insufficient to inform vaccine-associated risks in pregnancy. Thus, providers should vaccinate pregnant people needing HepB vaccination with Engerix-B, Recombivax HB, or Twinrix.

†† Pediarix cannot be administered at birth, before age 6 weeks, or at age ≥7 years.

§§ Vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age.

¶¶Twinrix is recommended for people aged ≥18 years who are at increased risk for both HAV and HBV infections.

Who should not receive hepatitis B vaccine?

Anyone who has had a serious allergic reaction to a prior dose of hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive hepatitis B vaccine. When hepatitis B vaccine is administered as part of a combination vaccine, contraindications to other vaccines should be checked.

Can a patient receive the first dose of hepatitis B vaccine from one manufacturer and subsequent doses from another manufacturer?

Yes. When feasible, vaccines from the same manufacturer should be used to complete the series, but vaccination should not be deferred when the manufacturer of the previously administered vaccine is unknown or when the vaccine from the same manufacturer is unavailable. Different vaccination schedules apply for patients receiving vaccines from different manufacturers; details regarding how to complete the vaccination series using vaccine from a different manufacturer are available. Data are limited on safety and immunogenicity when HepB-CpG is interchanged with HepB vaccines from other manufacturers (20). Data are limited on safety and immunogenicity when PreHevbrio is interchanged with HepB vaccines from other manufacturers.

If there is an interruption between doses of hepatitis B vaccine, does the vaccine series need to be restarted?

No. The series does not need to be restarted, but the following should be considered.

  • If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible.
  • The second and third doses should be separated by an interval of at least 8 weeks.
  • If only the third dose is delayed, it should be administered as soon as possible.

Is it harmful to administer an extra dose(s) of hepatitis B vaccine or repeat the entire vaccine series if documentation of vaccination history is unavailable?

No. If necessary, administering extra doses of single-antigen hepatitis B vaccine is not harmful.

Can hepatitis B vaccine be administered concurrently with other vaccines?

Yes. Administering hepatitis B vaccine at the same time as other vaccines has not been shown to interfere with antibody response. Separate body sites and syringes should be used for simultaneous administration of injectable vaccines.

How long does protection from hepatitis B vaccine last?

Studies indicate that immunologic memory remains intact for at least 30 years among healthy people who initiated hepatitis B vaccination at >6 months of age (21). The vaccine confers long-term protection against clinical illness and chronic hepatitis B virus infection. Cellular immunity appears to persist even though antibody levels might become low or decline below detectable levels (22). Among vaccinated cohorts who initiated hepatitis B vaccination at birth, long-term follow-up studies are ongoing to determine the duration of vaccine-induced immunity (21).

Why should an infant receive hepatitis B vaccine at birth before hospital discharge, even if the mother is negative for hepatitis B surface antigen (HBsAg)?

ACIP recommends that all infants receive hepatitis B vaccine at birth, regardless of the infection status of the mother (20). Infants born to HBV-infected mothers require hepatitis B vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth to protect them from infection. However, because errors or delays in testing, reporting, and documenting maternal HBsAg status can and do occur, administering the first dose of hepatitis B vaccine soon after birth to all infants acts as a safety net, reducing the risk for perinatal transmission when maternal HBsAg status is either unknown or incorrectly documented at delivery. Also, initiating the hepatitis B vaccine series at birth has been shown to increase a child’s likelihood of completing the vaccine series on schedule (20)

Should pregnant people be tested for HBV?

Yes. Pregnant people should receive HBsAg testing during each pregnancy, and those who are HBsAg-positive should have HBV DNA testing. AASLD recommends that pregnant people who test positive for HBsAg with HBV DNA levels of >200,000 IU/ML be provided antiviral therapy to reduce perinatal HBV transmission (23).

Can hepatitis B vaccine be given during pregnancy or lactation?

Yes. The hepatitis B vaccine contains no live virus, so neither pregnancy nor lactation should be considered a contraindication to vaccination. That said, data on Heplisav-B and PreHevbrio are currently insufficient to inform vaccine-associated risks in pregnancy and are not available to assess the effects on the breastfed infant or on milk production/excretion, thus providers should vaccinate pregnant people needing HepB vaccination with Engerix-B, Recombivax HB, or Twinrix. Limited experience suggests that the developing fetus is at no apparent risk for adverse effects when these hepatitis B vaccines are administered to pregnant people (24). Meanwhile, new HBV infection in a pregnant person might result in severe disease for the mother and chronic infection for the newborn. Pregnant people who are identified as being at risk for HBV infection during pregnancy should be vaccinated and counseled concerning other methods to prevent HBV infection. Pregnant people may be at increased risk for hepatitis B if they

  • have had more than one sex partner during the previous 6 months,
  • are being evaluated or treated for a sexually transmitted infection,
  • have had recent or current injection drug use, or
  • have had a sex partner who tested positive for HBsAg.

Can pregnant people get the HEPLISAV-B vaccine?

There are no published clinical studies of HEPLISAV-B in pregnant people. Available human data on HEPLISAV-B administered to pregnant people are insufficient to inform assessment of vaccine-associated risks in pregnancy. Until safety data are available for HEPLISAV-B, providers should continue to vaccinate pregnant people needing hepatitis B vaccina­tion with a vaccine from a different manufacturer.

Providers and patients can report administration of HEPLISAV-B to a pregnant people to the HEPLISAV-B® Pregnancy Registry, an observational study being conducted in the United States to evaluate pregnancy outcomes in people vaccinated with HEPLISAV-B® within 28 days prior to conception or at any time during pregnancy.

A pregnancy exposure registry is a study that collects health information from people who take prescription medicines or vaccines when they are pregnant.

Can pregnant people get the PreHevbrio vaccine?

There are no adequate and well-controlled studies of PreHevbrio in pregnant people. Available human data on PreHevbrio administered to pregnant people are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of PreHevbrio on the breastfed infant or on milk production/excretion.

There is a pregnancy exposure registry that monitors pregnancy outcomes in people exposed to PREHEVBRIO during pregnancy. People who receive PREHEVBRIO during pregnancy are encouraged to contact 1-888-421-8808 (toll-free).

A pregnancy exposure registry is a study that collects health information from people who take prescription medicines or vaccines when they are pregnant.

Can hepatitis B vaccine be given to immunocompromised people, such as people on hemodialysis or people with HIV?

Yes. A larger vaccine dose is required to induce protective antibody in patients on hemodialysis, and larger or additional doses might also be necessary for other immunocompromised people. Serologic testing of patients on hemodialysis and other immunocompromised people is recommended 1–2 months after administration of the final dose of the primary vaccine series to determine the need for revaccination. The safety and effectiveness of Heplisav-B and PreHevbrio have not been established in adults on hemodialysis. Detailed guidance on vaccination of patients on hemodialysis and other immunocompromised people is available from the Advisory Committee on Immunization Practices recommendations on adult hepatitis B vaccination [40 pages].

Can hepatitis B vaccine be given after exposure to HBV?

Yes. After a person has been exposed to HBV, appropriate prophylaxis, given as soon as possible but preferably within 24 hours, can effectively prevent infection. The mainstay of postexposure immunoprophylaxis is hepatitis B vaccine, but, in certain circumstances, the addition of HBIG provides increased protection (25,26).

Should people be tested for immunity to hepatitis B before being vaccinated?

Adult populations with risk factors for HBV transmission or at risk for HBV reactivation should receive complete serologic testing (HBsAg, anti-HBs, and anti-HBc) so they can be appropriately counseled, vaccinated, and/or linked to care and treatment. (See Who should be screened for HBV? for information about who should receive pre-vaccination testing.) Lack of access to serologic testing should not be a barrier to vaccination of susceptible people, especially in populations that are difficult to reach. Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended people should proceed.

The first vaccine dose should be administered immediately after collection of the blood sample for serologic testing. Vaccinating people who are immune to HBV infection because of current or previous infection or vaccination is not harmful and does not increase the risk for adverse events.

Is there any benefit in or risk associated with vaccinating a person who has been infected with HBV?

No. People who have already been infected with HBV will receive no benefit from vaccination. Vaccinating someone who is already infected poses no risk to the patient.

Who should receive postvaccination testing?

Testing for immunity is advised only for people whose subsequent clinical management depends on knowledge of their immune status, including

When should postvaccination testing be done in infants born to people who test positive for HBsAg?

For infants born to people who test positive for HBsAg, postvaccination testing should be performed 1–2 months after completion of ≥3 doses of a licensed hepatitis B vaccine series. Testing should not be performed before age 9 months in order to avoid detection of anti-HBs from hepatitis B immune globulin (HBIG) administered during infancy and to avoid detection of HBsAg from vaccine (HBsAg can be transiently positive for 1–18 days after vaccination). Testing at 9 months or later also maximizes detection of late HBV infection. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6439a6.htm

Management of Infants Born to Women with Hepatitis B Virus Infection for Pediatricians – September 2021

Can anti-HBs levels following vaccination decline over time?

Yes. Following vaccination, anti-HBs levels decline over time. Anti-HBs ≥10 mIU/mL is considered a correlate of vaccine-induced protection for people who have completed an approved vaccination series. Immunocompetent people who achieve an anti-HBs level ≥10 mIU/mL 1–2 months after completing the hepatitis B vaccine series remain protected, even if anti-HBs levels decline to <10 mIU/mL beyond that time (presumably because of persistent cellular immunity). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6210a1.htm

Are booster doses of hepatitis B vaccine recommended?

Booster doses are not recommended for people with normal immune status who have been vaccinated (21,27). Only certain people should receive a booster dose in specific situations. For patients on hemodialysis, if annual testing for antibody to hepatitis B surface antigen (anti-HBs) shows a decline to <10 mlU/mL, a booster dose should be administered. For other immunocompromised people (including those with HIV, hematopoietic stem-cell transplant recipients, and people receiving chemotherapy), the need for booster doses has not been determined. When anti-HBs levels decline to <10 mIU/mL, annual anti-HBs testing and booster doses should be considered for those with an ongoing risk for exposure.

References

1. Centers for Disease Control and Prevention. Viral hepatitis surveillance—United States, 2017. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019. Available at: https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm.
2. Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018. Hepatology. 2021.
3. Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, et al. An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. Hepatology. 2021.
4. Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. J Viral Hepat. 2019;26(5):596-602.
5. American Community Survey 1-Year Public Use Microdata Sample (PUMS) Files 2018. Variables Place of birth and decade of entry [Internet]. Suitland, MD: U.S. 2019.
6. Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis. 1991;11(2):73–83.
7. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1(8219):550–1
8. LeFevre ML. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: US Preventive Services Task Force recommendation statement. Annals Internal Med. 2014;161(1):58–66.
9. Lok AS, McMahon BJ. AASLD practice guideline update. Hepatology. 2009.
10. Weinbaum CM, Mast EE, Wang SA, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly Report 2008;19(57 [No. RR–8]):1–20.
11. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.
12. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med. 1979;300(3):101–6.
13. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942–56.
14. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.
15. Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167(11):794–804.
16. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
17. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092–100.
18. Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172–180.
19. Weng MK, Doshani M, Mohammed AK, et al. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Morbidity and Mortality Weekly Report 2022;71(13):477-483.
20. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018;67:455–8.
21. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22.
22. Middleman AB, Baker CJ, Kozinetz CA, et al. Duration of protection after infant hepatitis B vaccination series. Pediatrics 2014;133(6).
23. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324.
24. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018; 67(1);1–31.
25. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013;62(RR–10):1–19.
26. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR–11):1–52.
27. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53(1):68–75.